Ledaborbactam
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 4, 2024 (NCT06665555)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- ADC-14 proteinINHIBITOR
adc-14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCC(=O)N[C@H]1Cc2cccc(C(=O)O)c2OB1O- Mol. weight
- 263.06 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5093566 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06733675 | Phase 1 | Jan 7, 2025 | Department of Health and Human Services, VenatoRx Pharmaceuticals, Inc. |
| NCT06665555 | Phase 1 | Nov 4, 2024 | National Institute of Allergy and Infectious Diseases (NIAID), VenatoRx Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VenatoRx Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2024 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2025 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1